Clinical Trial Update: Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating capmatinib with osimertinib in second-line non-small cell lung cancer was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Capmatinib (capmatinib)
• Osimertinib (osimertinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: TERMINATED | Results posted: 2023-10-30